ReachMD

Episodes 1-15 of 71

• • 

    

    Peter K. Kaiser, MD

    Peer

  • 

    

    Dante J. Pieramici, MD

    Peer

  2

  

  RestartResume

  Neovascular AMD and RVO: Distinguishing the Differential

  Neovascular AMD and RVO: Distinguishing the Differential

  0.25 credits

• • 

    

    Mark T. Dunbar, OD, FAAO

    Peer

  • 

    

    Julia Haller, MD

    Peer

  • 

    

    Charles Wykoff, MD, PhD

    Peer

  • 

    

    Emily Chew, MD

    Peer

  0

  

  RestartResume

  Time Is Vision: A Call to Action for Earlier Intervention to Prevent Blindness Due to nAMD and RVO

  Time Is Vision: A Call to Action for Earlier Intervention to Prevent Blindness Due to nAMD and RVO

• • 

    

    Charles Wykoff, MD, PhD

    Peer

  1

  

  RestartResume

  Seeing Eye to Eye: Case Series on Treatment Strategies for Neovascular AMD

  Seeing Eye to Eye: Case Series on Treatment Strategies for Neovascular AMD

  0.25 credits

• • 

    

    Adrienne W. Scott, MD

    Peer

  • 

    

    Peter A. Campochiaro, MD

    Peer

  • 

    

    Rahul N. Khurana, MD

    Peer

  2

  

  RestartResume

  Seeing Eye to Eye: Case Series on Treatment Strategies for RVO

  Seeing Eye to Eye: Case Series on Treatment Strategies for RVO

  0.25 credits

• • 

    

    Diana Shechtman, OD, FAAO

    Peer

  • 

    

    Mark T. Dunbar, OD, FAAO

    Peer

  2

  

  RestartResume

  Time Is Vision: The Critical Role of Early Diagnosis and Referral in Neovascular AMD and RVO

  Time Is Vision: The Critical Role of Early Diagnosis and Referral in Neovascular AMD and RVO

  0.25 credits

• • 

    

    Neil Bressler, MD

    Peer

  0

  

  RestartResume

  Take Control of Wet AMD

  Take Control of Wet AMD

• • 

    

    Emily Chew, MD

    Peer

  • 

    

    Neil Bressler, MD

    Peer

  • 

    

    Joseph M. Coney, MD

    Peer

  • 

    

    Steven Ferrucci, OD, FAAO

    Peer

  2

  

  RestartResume

  nAMD and RVO: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

  nAMD and RVO: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

  0.25 credits

• • 

    

    Diana V. Do, MD

    Peer

  • 

    

    Julia Haller, MD

    Peer

  • 

    

    Rishi P. Singh, MD

    Peer

  1

  

  RestartResume

  Optimizing Vision Outcomes in nAMD

  Optimizing Vision Outcomes in nAMD

  0.25 credits

• • 

    

    Julia Haller, MD

    Peer

  3

  

  RestartResume

  Time Is Vision: Improving Your Diagnostic Skills

  Time Is Vision: Improving Your Diagnostic Skills

  0.25 credits

• • 

    

    Michael S. Ip, MD

    Peer

  • 

    

    Christina Y. Weng, MD, MBA

    Peer

  2

  

  RestartResume

  Time Is Vision: Early Recognition and Management of Neovascular AMD and RVO

  Time Is Vision: Early Recognition and Management of Neovascular AMD and RVO

  0.25 credits

• • 

    

    Arshad M. Khanani, MD, MA

    Peer

  • 

    

    Dante J. Pieramici, MD

    Peer

  4

  

  RestartResume

  Meeting Eye-to-Eye: A Patient-Provider Exchange on Improving Treatment in nAMD Through Sustained Delivery

  Meeting Eye-to-Eye: A Patient-Provider Exchange on Improving Treatment in nAMD Through Sustained Delivery

  0.50 credits

• • 

    

    Pradeep Y. Ramulu, MD, PhD

    Peer

  • 

    

    E. Randy Craven, MD

    Peer

  • 

    

    Mark T. Dunbar, OD, FAAO

    Peer

  8

  

  RestartResume

  Innovations in Glaucoma Therapy

  Innovations in Glaucoma Therapy

  0.25 credits

• • 

    

    Rishi P. Singh, MD

    Peer

  • 

    

    Sophie J. Bakri, MD

    Peer

  • 

    

    Dilsher S. Dhoot, MD

    Peer

  • 

    

    David Eichenbaum, MD

    Peer

  9

  

  RestartResume

  Managing COVID-19 Related Delays In Patients with Neovascular AMD

  Managing COVID-19 Related Delays In Patients with Neovascular AMD

  1.00 credits

• • 

    

    Pradeep Y. Ramulu, MD, PhD

    Peer

  • 

    

    Ian Benjamin Gaddie, OD, FAAO

    Peer

  9

  

  RestartResume

  Glaucoma: Therapeutic Advances on the Cutting Edge

  Glaucoma: Therapeutic Advances on the Cutting Edge

  0.25 credits

• • 

    

    Mark Dunbar, OD, FAAO

    Peer

  • 

    

    Diana V. Do, MD

    Peer

  5

  

  RestartResume

  A National Eye Institute Initiative—Ensuring the Health of Patients and Staff in Eye Health Practices During COVID-19

  A National Eye Institute Initiative—Ensuring the Health of Patients and Staff in Eye Health Practices During COVID-19

  0.25 credits

• 1
• 2
• 3
• 4
• 5
• Next